A closer look at the Zenvo takeover at The Shmuseum, featuring a full showcase of the brand’s latest hypercars. This video ...

Join me on a 7-day adventure exploring Alaska aboard the Norwegian Encore, starting from Seattle. This video highlights my ...

MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine ...

MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106177990/en/ ...

New Delhi [India], November 6 (ANI): The resurgence of gold as a principal reserve asset highlights a major transformation in the global financial system, according to a report by CareEdge Ratings. As ...

- Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent ...

– Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025 – – Initiated Phase 1 healthy adult trial of EDG-15400 for ...

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for ...